{"product_id":"sght-vrio-analysis","title":"Sight Sciences, Inc. (SGHT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Sight Sciences, Inc. (SGHT) truly built for the long haul? This concise VRIO analysis cuts straight to the core, revealing precisely where its competitive edge lies - or where it's missing - across Value, Rarity, Inimitability, and Organization. Dive in below to see the distilled verdict on Sight Sciences, Inc. (SGHT)'s path to sustainable success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 1. OMNI Surgical System Technology (Glaucoma MIGS)Value: Enables implant-free, minimally invasive glaucoma surgery (MIGS) to reduce intraocular pressure, capturing $19.7 million in revenue in Q3 2025.\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core revenue driver for Sight Sciences, Inc. (SGHT) right now, the OMNI Surgical System. It’s an implant-free, minimally invasive glaucoma surgery (MIGS) tool that lets surgeons address all three known outflow resistance points. That focus is paying off, as Surgical Glaucoma revenue hit \u003cstrong\u003e$19.7 million\u003c\/strong\u003e in the third quarter of 2025 alone. That’s the value proposition right there: a single device for comprehensive treatment.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how this technology stacks up against the competition using the VRIO lens.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Dimension\u003c\/th\u003e\n\u003cth\u003eAssessment for OMNI Surgical System\u003c\/th\u003e\n\u003cth\u003eKey Supporting Data\/Observation\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eGenerated \u003cstrong\u003e$19.7 million\u003c\/strong\u003e in Surgical Glaucoma revenue in Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eSight Sciences claims the number one position in implant-free MIGS, though other stent players exist.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eDifficult (Short-Term)\u003c\/td\u003e\n\u003ctd\u003eSpecialized engineering, like the newer OMNI Edge with TruSync technology, creates a barrier.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eStrong\u003c\/td\u003e\n\u003ctd\u003eEvidenced by reaching an all-time high of \u003cstrong\u003e1,197\u003c\/strong\u003e ordering accounts as of Q3 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eStrong technology, but the market demands constant innovation, like the OMNI Edge launch in April 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe system is definitely valuable because it’s driving the bulk of the company’s top line. What this estimate hides is the pressure from Medicare coverage restrictions impacting account utilization, which partially offset revenue growth in Q3 2025.\u003c\/p\u003e\n\n\u003cp\u003eOn Rarity, while MIGS isn't new, the implant-free, dually-indicated approach is less common than some alternatives. Still, the company is the leading player in that specific implant-free niche.\u003c\/p\u003e\n\n\u003cp\u003eImitability is where you see the moat start to form, but it’s not impenetrable. The specialized engineering, especially with the newer OMNI Edge system featuring patented TruSync technology, makes it tough to copy quickly. Still, a well-funded competitor can throw R\u0026amp;D dollars at this over time.\u003c\/p\u003e\n\n\u003cp\u003eOrganizationally, things look solid for now. They have the structure to support the product, shown by that account count. Also, the recent executive appointments in November 2025 suggest management is focused on scaling.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThe OMNI Edge offers \u003cstrong\u003e21 µL\u003c\/strong\u003e viscoelastic capacity, nearly double the original OMNI’s \u003cstrong\u003e11 µL\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company is targeting high single-digit growth in surgical glaucoma in the intermediate term.\u003c\/li\u003e\n\u003cli\u003eManagement is focused on achieving break-even without needing new equity capital.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe current advantage is temporary because the market is hyper-competitive. To sustain this, Sight Sciences, Inc. (SGHT) needs to keep pushing the envelope, like they did with the OMNI Edge debut in April 2025.\u003c\/p\u003e\n\u003cp\u003eFinance: Draft a sensitivity analysis on the impact of a \u003cstrong\u003e10%\u003c\/strong\u003e decline in account utilization for Q4 2025 by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 2. TearCare System Technology (Dry Eye)Value: Offers a non-surgical, in-office, localized heat therapy targeting the underlying cause of evaporative dry eye disease (MGD).\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe TearCare System provides a non-surgical, in-office, localized heat therapy designed to address the underlying cause of evaporative dry eye disease, Meibomian Gland Dysfunction (MGD).\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe specific design featuring a wearable, open-eye device for MGD treatment is considered rare in the current market.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe difficulty in copying the technology stems from the requirement for specialized hardware design and the development of a specific clinical protocol.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company's organization is actively developing to exploit the technology by prioritizing reimbursed market access over immediate sales volume. This strategic focus is evidenced by the Dry Eye revenue performance in the third quarter of 2025, which was only \u003cstrong\u003e$0.2 million\u003c\/strong\u003e, a significant decrease from \u003cstrong\u003e$1.5 million\u003c\/strong\u003e in the third quarter of 2024. The Dry Eye gross margin for Q3 2025 was \u003cstrong\u003e38%\u003c\/strong\u003e, down from \u003cstrong\u003e48%\u003c\/strong\u003e in Q3 2024.\u003c\/p\u003e\n\u003cp\u003eKey organizational milestones supporting future exploitation include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe establishment of jurisdiction-wide pricing for CPT code \u003cstrong\u003e0563T\u003c\/strong\u003e by two Medicare Administrative Contractors (MACs): Novitas Solutions and First Coast Service Options.\u003c\/li\u003e\n\u003cli\u003eThese two MACs cover an estimated \u003cstrong\u003e10.4 million\u003c\/strong\u003e Medicare fee-for-service covered lives, representing approximately \u003cstrong\u003e30%\u003c\/strong\u003e of the total.\u003c\/li\u003e\n\u003cli\u003eThe Medicare fee schedule amount for \u003cstrong\u003e0563T\u003c\/strong\u003e is effective for dates of service on or after \u003cstrong\u003eJanuary 1, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe following table summarizes key financial and reimbursement metrics related to the TearCare System's organizational strategy as of Q3 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry Eye Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Year Dry Eye Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry Eye Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Year Dry Eye Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCovered Lives with New MAC Pricing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovitas \u0026amp; First Coast Jurisdictions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePercentage of Total Medicare FFS Lives Covered\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~30%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNovitas \u0026amp; First Coast Jurisdictions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eA sustained competitive advantage is anticipated if reimbursement traction continues, as the unique procedure-based model is difficult for competitors relying on drop-based treatments to match. Health economic data supports this position:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eA Cost-Utility Analysis demonstrated that TearCare resulted in \u003cstrong\u003e$903\u003c\/strong\u003e lower per-patient annual costs compared to Cyclosporine 0.05% (CsA).\u003c\/li\u003e\n\u003cli\u003eTearCare showed an incremental benefit of \u003cstrong\u003e0.014 Quality-Adjusted Life Years (QALYs)\u003c\/strong\u003e over CsA in the same analysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company raised its full-year 2025 revenue guidance to \u003cstrong\u003e$76.0 million to $78.0 million\u003c\/strong\u003e, up from a prior range of $72.0 million to $76.0 million, reflecting confidence in the overall strategy, including the TearCare reimbursement progress.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 3. Reimbursement Strategy \u0026amp; MAC AccessValue: Securing CPT code pricing for the TearCare procedure, which is key to provider adoption and high-margin recurring revenue.\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Securing jurisdiction-wide pricing for CPT code \u003cstrong\u003e0563T\u003c\/strong\u003e, effective for dates of service on or after \u003cstrong\u003eJanuary 1, 2025\u003c\/strong\u003e. The established fee schedule amount for CPT code 0563T is reported as \u003cstrong\u003e$1,142\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Achieving favorable Medicare Administrative Contractor (MAC) coverage is a significant hurdle in med-tech, evidenced by the current coverage being limited to two MAC jurisdictions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e This is a regulatory and administrative moat built over years of clinical data submission, resulting in established pricing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Q3 2025 saw wins with First Coast Service Options (FCSO) and Novitas Solutions, covering an estimated \u003cstrong\u003e10.4 million\u003c\/strong\u003e Medicare fee-for-service covered lives. This represents approximately \u003cstrong\u003e30%\u003c\/strong\u003e of total Medicare fee-for-service covered lives nationwide. The company launched the Sight Access Portal to assist providers with benefit verifications and reimbursement.\u003c\/p\u003e\n\u003cp\u003eThe Dry Eye segment revenue in Q3 2025 was \u003cstrong\u003e$0.2 million\u003c\/strong\u003e, a decrease of \u003cstrong\u003e88%\u003c\/strong\u003e compared to Q3 2024, reflecting the strategic focus on achieving reimbursed market access for TearCare. Full year 2025 Dry Eye revenue guidance was updated to expect \u003cstrong\u003e$500,000 to $1 million\u003c\/strong\u003e in Q4 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e This administrative success creates a barrier to entry for other interventional dry eye players. The following table details the initial MAC coverage expansion:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMAC\u003c\/td\u003e\n\u003ctd\u003eStates \/ Regions Covered\u003c\/td\u003e\n\u003ctd\u003eEstimated Covered Lives\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovitas Solutions, Inc.\u003c\/td\u003e\n\u003ctd\u003eArkansas, Colorado, District of Colombia, Delaware, Louisiana, Maryland, Mississippi, New Jersey, New Mexico, Oklahoma, Pennsylvania, and Texas\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFirst Coast Service Options, Inc. (FCSO)\u003c\/td\u003e\n\u003ctd\u003eFlorida, Puerto Rico, Virgin Islands\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe combined coverage from these two MACs is estimated at \u003cstrong\u003e10.4 million\u003c\/strong\u003e lives.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this administrative success creates a barrier to entry for other interventional dry eye players.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 4. Surgical Glaucoma Commercial FootprintValue: A broad installed base of surgeons actively ordering glaucoma devices, driving consistent revenue despite utilization headwinds.\n\u003c\/h2\u003e\n\u003cp\u003eThe Surgical Glaucoma segment generated $19.7 million in revenue for the third quarter of 2025, representing a 6% increase compared to the third quarter of 2024. Total company revenue for Q3 2025 was $19.9 million.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eYoY Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Glaucoma Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Glaucoma Ordering Accounts\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,197\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e+8%\u003c\/strong\u003e (vs Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Glaucoma Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFlat (vs Q3 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTariff COGS Impact (Surgical Glaucoma)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity: Moderately rare; 1,197 ordering accounts is a solid base for a focused medical device company.\u003c\/h3\u003e\n\u003cp\u003eThe Surgical Glaucoma ordering accounts reached an all-time high of 1,197 in Q3 2025. This represents an 8% increase from the 1,174 accounts reported in the second quarter of 2025.\u003c\/p\u003e\n\u003ch3\u003eImitability: Difficult; building a trained sales force and surgeon relationships takes significant time and capital.\u003c\/h3\u003e\n\u003cp\u003eThe time and capital required to build a trained sales force and establish surgeon relationships represent barriers to imitation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company's sales force and surgeon relationships are built over time.\u003c\/li\u003e\n\u003cli\u003eExpansion of the commercial footprint requires significant capital investment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization: Effective; they grew ordering accounts 8% year-over-year in Q3 2025, showing sales execution strength.\u003c\/h3\u003e\n\u003cp\u003eThe organization demonstrated execution strength by increasing Surgical Glaucoma ordering accounts by 8% year-over-year in Q3 2025, contributing to a 6% increase in Surgical Glaucoma revenue for the quarter.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage: Temporary; while strong now, utilization challenges (like Medicare restrictions) show this base is sensitive to external policy.\u003c\/h3\u003e\n\u003cp\u003eLower account utilization in Q3 2025 was primarily due to coverage restrictions on performing multiple MIGS procedures in combination with cataract surgery for Medicare patients in most states.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedicare coverage restrictions impacted account utilization.\u003c\/li\u003e\n\u003cli\u003eSurgical Glaucoma revenue growth of 6% was achieved despite utilization headwinds.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 5. Interventional Eye Care Platform FocusValue: A clear, unified strategy to transform care by targeting underlying causes with minimally invasive\/non-invasive solutions for two major diseases.\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe dual focus is reflected in the revenue composition, with Surgical Glaucoma being the dominant revenue stream, consistent with the strategy of targeting major prevalent eye diseases.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod End Date\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Glaucoma Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$18.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry Eye Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Glaucoma Revenue\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$75.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry Eye Revenue\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eDual platform focus in ophthalmic medical devices is less common.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eStrategic vision execution requires consistent financial commitment.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eResearch and Development Expenses (Q4 2024): \u003cstrong\u003e$4.3 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eResearch and Development Expenses (Q2 2025): \u003cstrong\u003e$4.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eManagement is executing the dual focus, evidenced by the strategic prioritization of Dry Eye market access over short-term revenue.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment\u003c\/td\u003e\n\u003ctd\u003ePeriod\u003c\/td\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry Eye Revenue\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry Eye Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry Eye Revenue Decline (YoY)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e88%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Glaucoma Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe strategic shift in Dry Eye is explicitly noted:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDry Eye revenue in Q3 2025 decreased primarily due to fewer SmartLids® sales, a result of the Company's focus on achieving reimbursed market access for TearCare procedures.\u003c\/li\u003e\n\u003cli\u003eFull Year 2025 Revenue Guidance assumes Dry Eye revenue of approximately \u003cstrong\u003e$1.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe strategic direction supports sustained operational efficiency, as indicated by gross margins.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross Margin (Full Year 2024): \u003cstrong\u003e85%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSurgical Glaucoma Gross Margin (Full Year 2024): \u003cstrong\u003e88%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDry Eye Gross Margin (Full Year 2024): \u003cstrong\u003e46%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 6. Intellectual Property \u0026amp; TrademarksValue: Legal protection for core product names (OMNI, TearCare) and underlying technology, preventing direct copying.\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Legal protection for core product names (OMNI, TearCare) and underlying technology, preventing direct copying.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOMNI Surgical System may be covered by one or more U.S. patents, including U.S. Patent Nos. 7,909,789 through \u003cstrong\u003e12,350,192\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTearCare System may be covered by one or more U.S. patents, including U.S. Patent Nos. 9,510,972 through \u003cstrong\u003e12,263,115\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSION Surgical System may be covered by U.S. Patent Nos. \u003cstrong\u003e11,877,954\u003c\/strong\u003e and \u003cstrong\u003e12,310,891\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSight Sciences received a $34 million positive jury trial verdict in a patent infringement case against Alcon, filed September 16, 2021.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Common; most device companies have IP, but the breadth across two distinct platforms is valuable.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe portfolio covers two distinct platforms: Surgical Glaucoma (OMNI, SION) and Dry Eye (TearCare).\u003c\/li\u003e\n\u003cli\u003eAs of April 30, 2021, the company owned eight U.S. trademark registrations and one pending E.U. trademark application.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; patents are legally protected, though competitors can design around them.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMultiple U.S. patent applications are pending for both OMNI and TearCare technologies.\u003c\/li\u003e\n\u003cli\u003eResearch and development expenses were $18.0 million in full year 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Adequate; trademarks are registered in key territories like the US and EU for OMNI.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eRegistration Territory\u003c\/th\u003e\n\u003cth\u003eStatus\/Count Reference Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMNI Trademark\u003c\/td\u003e\n\u003ctd\u003eUnited States, European Union, and other territories\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTearCare Trademark\u003c\/td\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003eCurrent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Trademark Registrations\u003c\/td\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003eEight as of April 30, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE.U. Trademark Application\u003c\/td\u003e\n\u003ctd\u003eEuropean Union\u003c\/td\u003e\n\u003ctd\u003eOne pending as of April 30, 2021\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; patents expire, and legal defense is costly, but it buys crucial time.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal operating expenses decreased by 6% in full year 2024 compared to $126.4 million in full year 2023, with lower legal expenses contributing to the decrease.\u003c\/li\u003e\n\u003cli\u003eThe company expects adjusted operating expenses for full year 2025 to range from $105.0 million to $107.0 million.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 7. Financial Position (Cash Runway)Value: Sufficient capital to fund operations and growth without immediate need for dilutive financing, aiming for break-even.\n\u003c\/h2\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eSufficient capital\u003c\/strong\u003e to fund operations and growth without immediate need for dilutive financing, aiming for break-even.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eModerately rare; many smaller firms struggle with cash burn.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eNot applicable; this is a current state, not a repeatable process.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eDisciplined; cash and equivalents stood at \u003cstrong\u003e$92.4 million\u003c\/strong\u003e against \u003cstrong\u003e$40.0 million\u003c\/strong\u003e in long-term debt as of September 30, 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$92.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$101.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Long-Term Debt (before discount\/costs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Quarter\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated for Q2 2025 in the same context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary; cash reserves are finite and depleted by operating losses.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Total Revenue: \u003cstrong\u003e$19.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Loss: \u003cstrong\u003e$8.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Cash Used: \u003cstrong\u003e$9.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Total Operating Expenses: \u003cstrong\u003e$25.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted Operating Expenses: \u003cstrong\u003e$19.8 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Total Gross Margin: \u003cstrong\u003e86%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 8. Operational Efficiency\/Cost StructureValue: Demonstrated ability to reduce overhead and operating expenses while maintaining high gross margins in the core segment.\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrated ability to reduce overhead and operating expenses while maintaining high gross margins in the core segment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare; achieving cost discipline during growth is tough.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires deep operational restructuring and supply chain management.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Improving; total operating expenses fell \u003cstrong\u003e11%\u003c\/strong\u003e to \u003cstrong\u003e$25.1 million\u003c\/strong\u003e in Q3 2025, following a reduction in force.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; cost savings are often one-time or require constant vigilance to maintain.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics illustrating operational efficiency for the third quarter ended September 30, 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003ePrior Period Value\u003c\/td\u003e\n\u003ctd\u003eChange\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$28.1 million\u003c\/strong\u003e (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-11%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e86%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e84%\u003c\/strong\u003e (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+2 percentage points\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgical Glaucoma Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e87%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e87%\u003c\/strong\u003e (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eFlat\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDry Eye Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48%\u003c\/strong\u003e (Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-10 percentage points\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eRestructuring costs associated with the reduction in force announced on August 27, 2025, totaled \u003cstrong\u003e$2.8 million\u003c\/strong\u003e in Q3 2025. Surgical Glaucoma cost of goods sold associated with tariffs was \u003cstrong\u003e$0.4 million\u003c\/strong\u003e in Q3 2025.\u003c\/p\u003e\n\u003cp\u003eThe company reduced its full year 2025 adjusted operating expenses guidance to \u003cstrong\u003e$90 million to $92 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eFurther details on expense components and segment performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal operating expenses of \u003cstrong\u003e$25.1 million\u003c\/strong\u003e in Q3 2025 were primarily due to lower stock-based compensation expense, personnel-related expenses, and research and development expenses.\u003c\/li\u003e\n\u003cli\u003eSurgical Glaucoma revenue was \u003cstrong\u003e$19.7 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e6%\u003c\/strong\u003e compared to Q3 2024.\u003c\/li\u003e\n\u003cli\u003eDry Eye revenue was \u003cstrong\u003e$0.2 million\u003c\/strong\u003e, a decrease from \u003cstrong\u003e$1.5 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSight Sciences, Inc. (SGHT) - VRIO Analysis: 9. Clinical Data Portfolio (SAHARA RCT)Value: Long-term, peer-reviewed data (24-month results) proving the durability of the TearCare procedure, which is vital for payer confidence.\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Long-term, peer-reviewed data (24-month results) proving the durability of the TearCare procedure, which is vital for payer confidence.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; long-term (2-year) RCT data is a high bar in this space.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very difficult; running a high-quality, multi-year randomized controlled trial is expensive and time-consuming.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Supportive; this data directly supports the reimbursement push and physician education efforts.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; high-quality, long-term clinical proof is a powerful, hard-to-replicate asset.\u003c\/p\u003e\n\n\u003cp\u003eThe SAHARA RCT (NCT04795752) tracked 166 participants through 24 months.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eBaseline Value\u003c\/td\u003e\n\u003ctd\u003e24-Month Mean Value\u003c\/td\u003e\n\u003ctd\u003eStatistical Significance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTear Break-up Time (TBUT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4.41 seconds\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6.29–7.13 seconds\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eP\u0026lt;.0001\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMeibomian Gland Secretion Score (MGSS)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.26\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.68 to 18.95\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cem\u003eP\u0026lt;.0001\u003c\/em\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetreatment Required (Post-2 Treatments)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e66%\u003c\/strong\u003e required no further therapy\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian Time to Retreatment\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7 months\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSubjective assessments demonstrated sustained improvement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOSDI at Month 6: \u003cstrong\u003e31.9\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eOSDI at Month 24: \u003cstrong\u003e50.3\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSANDE at Month 6: \u003cstrong\u003e40.2\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eSANDE at Month 24: \u003cstrong\u003e66.8\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: 13-Week Cash Flow View Incorporating Q3 Usage (Based on Q3 2025 Actuals)\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow Component\u003c\/td\u003e\n\u003ctd\u003eAmount (USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash (as of 6\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$101.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Quarter (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRestructuring Costs Included in Cash Used (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$92.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516249301141,"sku":"sght-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sght-vrio-analysis.png?v=1740214986","url":"https:\/\/dcf-model.com\/fr\/products\/sght-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}